Abstract: The present invention describes a mutant human tissue factor protein which binds functional Factor VII/VIIa but is substantially free of functional procoagulant cofactor activity, and compositions containing the mutant protein. Also disclosed are methods for using the mutant human tissue factor proteins, and recombinant DNA vectors for expressing the protein.
Abstract: The present invention relates to optionally substituted, non-toxic peptides and derivatives capable of inhibiting superoxide production in phagocytic cells. The invention also relates to compositions and methods useful in inhibiting inflammation and in treating inflammatory disorders such as autoimmune disorders, gout, adult respiratory distress syndrome, asthma, myocardial infarction, and various dermatological disorders.The present invention contemplates compositions derived from low molecular weight GTP-binding proteins (LMWG), mastoparan, GAP proteins, and related peptides. The invention further contemplates compositions useful in inhibiting activation of NADPH oxidase or in promoting GDP/GTP exchange. Therapeutic compositions containing various inhibitors, and methods of using same, are also disclosed.
Abstract: Compositions containing two species of indolyl-3-alkane alpha-hydroxylase (INDH) are isolated from Pseudomonas XA. An INDH1 composition contains protein subunits having molecular weights of 75,000, 34,500 and 32,500 daltons. An INDH2 composition contains protein subunits having molecular weights of 60,000, 44,000 and 42,000 daltons. Molecular weights are determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The compositions have a Specific INDH Activity of at least 10 international Units of INDH activity per milligram of protein, and contain less than 1 nanogram of endotoxin per International Unit of Specific INDH Activity. The INDH compositions may be immobilized on an insoluble matrix such as silica beads to provide at least 2.5 international Units of INDH activity per gram of Immobilized INDH composition. The INDH compositions are isolated by lysing Pseudomonas XA cells at a temperature of no more than 15.degree. C.
Type:
Grant
Filed:
May 16, 1996
Date of Patent:
March 3, 1998
Assignee:
Automedix Sciences, Inc.
Inventors:
Robert L. Murtfeldt, Allan J. Bream, Kathryn K. McCarthy
Abstract: The present invention describes an encoded combinatorial chemical library comprised of a plurality of bifunctional molecules having both a chemical polymer and an identifier oligonucleotide sequence that defines the structure of the chemical polymer. Also described are the bifunctional molecules of the library, and methods of using the library to identify chemical structures within the library that bind to biologically active molecules in preselected binding interactions.
Type:
Grant
Filed:
June 18, 1996
Date of Patent:
March 3, 1998
Assignee:
The Scripps Research Institute
Inventors:
Richard Lerner, Kim Janda, Sydney Brenner
Abstract: Antigens, immunogens, inocula, antibodies, and particularly diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. The diagnostic methods and systems utilize a synthetic, random copolymer polypeptide containing about 6 to about 40 amino acid residues having a sequence corresponding to the sequence of a CMV-encoded polypeptide antigen. The diagnostic methods and systems are particularly useful in identifying infections mononucleosis during its acute phase.
Abstract: The present invention describes a rapid method for the identification of compounds/reagents which inhibit lipopolysaccharide (LPS) binding to LPS binding protein (LBP), and kits for practicing the method.
Type:
Grant
Filed:
March 2, 1994
Date of Patent:
January 6, 1998
Assignee:
The Scripps Research Institute
Inventors:
Douglas N. Mintz, Peter Tobias, Richard Ulevitch
Abstract: The present invention describes polypeptides and anti-peptide antibodies capable of inhibiting serine protease enzymatic activity. In particular, polypeptides and anti-peptide antibodies derived from the blood coagulation serine proteases Factor VIIa, Factor IXa, Factor Xa, Factor XIa, thrombin and plasma kallikrein are described that are capable of inhibiting coagulation. The polypeptide and antibody are useful in methods and systems for inhibiting serine proteases, and particularly for inhibiting blood coagulation processes mediated by serine proteases in vitro or in a human patient.
Abstract: The present invention describes methods for producing metal binding sites on polypeptides, and particularly for producing metal binding sites within the CDR regions of immunoglobulin heavy or light chains that are displayed on the surface of filamentous phage particles. The invention also describes oligonucleotides useful for preparing the metal binding sites, and human monoclonal antibodies produced by the present methods.
Type:
Grant
Filed:
June 14, 1993
Date of Patent:
October 21, 1997
Assignee:
The Scripps Research Institute
Inventors:
Carlos F. Barbas, Jonathan Rosenblum, Richard A. Lerner
Abstract: The present invention describes methods for producing antibody libraries, and particularly for increasing antibody library diversity by inducing mutagenesis within the CDR regions of immunoglobulin heavy or light chains that are displayed on the surface of filamentous phage particles comprising the library. The invention also describes oligonucleotides useful for increasing the library diversity, and universal light chains useful in the library production methods.
Type:
Grant
Filed:
September 2, 1994
Date of Patent:
September 16, 1997
Assignee:
The Scripps Research Institute
Inventors:
Carlos F. Barbas, Dennis R. Burton, Richard A. Lerner
Abstract: Novel hybridoma cell lines producing monoclonal antibodies which react specifically with human pancreatic cancer cells are described. Methods for producing antigenic preparations to generate the hybridoma cell lines and for selecting, purifying and characterizing the monoclonal antibodies reactive with human cells, including pancreatic cancer cells, are disclosed. The antigens to which the antibodies of the invention are specific are characterized.
Abstract: The invention describes a metal binding protein capable of forming a coordination complex with a metal cation. The protein contains a sequence of amino acid residues that defines a variable domain of an immunoglobulin light chain having a L1 region and a L3 region, and also contains three contact amino acid residues in the variable domain that participate as ligands for the metal coordination complex.
Type:
Grant
Filed:
November 22, 1994
Date of Patent:
September 9, 1997
Assignee:
The Scripps Research Institute
Inventors:
Richard A. Lerner, Victoria A. Roberts, Elizabeth D. Getzoff, John A. Tainer, Stephen J. Benkovic
Abstract: The present invention contemplates a system and formulations for preparing cell culture medium useful for growing cells for the purpose of producing and isolating nucleic acids. Dry-concentrate culture medium compositions are described as packaged in unit dose form such as in dissolvable capsules.
Abstract: Filamentous phage comprising a matrix of cpVIII proteins encapsulating a genome encoding first and second polypeptides of an antogenously assembling receptor, such as an antibody, and a receptor comprised of the first and second polypeptides surface-integrated into the matrix via a filamentous phage coat protein membrane anchor domain fused to at least one of the polypeptides.
Type:
Grant
Filed:
June 8, 1994
Date of Patent:
August 19, 1997
Assignee:
The Scripps Research Institute
Inventors:
Carlos Barbas, Angray Kang, Richard A. Lerner
Abstract: Methods are described for characterizing platelet aggregation defects. The defects are characterized as activation, ligand binding, or post-occupancy defects. In one embodiment of the invention a Cam variant of Glanzmann's thrombasthenia is characterized as having a ligand binding defect. In another embodiment, a patient with myelofibrosis is identified as having an activation defect. Rapid analysis are afforded using fluorescence-activated flow cytometry. Also, diagnostic kits are described which comprise antibodies suitable for characterizing the above defects.
Abstract: The present invention describes human monoclonal antibodies which immunoreact with and neutralize human immunodeficiency virus (HIV). Also disclosed are immunotherapeutic and diagnostic methods of using the monoclonal antibodies, as well as cell line for producing the monoclonal antibodies.
Type:
Grant
Filed:
July 18, 1994
Date of Patent:
July 29, 1997
Assignee:
The Scripps Research Institute
Inventors:
Dennis R. Burton, Carlos F. Barbas, Richard A. Lerner
Abstract: Lambdoid phage comprising a matrix of proteins encapsulating a genome encoding first and second polypeptides of an autogenously assembling receptor and a receptor comprised of the first and second polypeptides surface-integrated into the matrix via a lambdoid phage tail protein matrix anchor domain fused to at least one of the polypeptides.
Type:
Grant
Filed:
August 5, 1994
Date of Patent:
May 6, 1997
Assignee:
The Scripps Research Institute
Inventors:
Ichiro Maruyama, Hiroko Maruyama, Sydney Brenner
Abstract: DNA segments that include DNA sequences defining a structural gene coding for a human tissue factor heavy chain protein and a precursor form of that protein are disclosed. Recombinant DNA molecules capable of expressing a human tissue factor heavy chain protein are also disclosed. Further disclosed are human tissue factor heavy chain binding site polypeptide analogs as well as methods for their use.
Type:
Grant
Filed:
April 29, 1992
Date of Patent:
April 22, 1997
Assignee:
The Scripps Research Institute
Inventors:
Thomas S. Edgington, James H. Morrissey
Abstract: A centrifugal rotor effects the isolation, in a sequence of steps, of a substance from a mixture of substances dissolved, suspended or dispersed in a sample liquid. Multiple samples are processed simultaneously by means of a plurality of fractionation cells, each of which contains a series of interconnected, chambered and vented compartments in which individual steps of the fractionation and isolation procedure take place. Specific steps in the preferred embodiments include lysis, sedimentation, aggregation, sorption, rinsing, and desorption. The specific compartment occupied by the sample liquid or one of its fractions at any stage of the process is governed by the speed and direction of rotation of the rotor and by gravitational force. The interconnections, chambers and passages of each compartment are sized and angled to prevent predetermined amounts of sample and reagent liquids from overflowing the compartment.
Type:
Grant
Filed:
February 24, 1993
Date of Patent:
March 11, 1997
Inventors:
David R. Beritashvili, Maxim V. Myakishev, Gennady M. Ershov, George P. Georgiev, George I. Kapanadze
Abstract: The present invention contemplates therapeutic compositions containing a fibrinogen homolog capable of binding to endothelial cells in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Also described are therapeutic compositions containing an ICAM-1 homolog capable of binding to fibrinogen in an RGD-independent manner that inhibits fibrinogen binding to endothelial cells. Methods of inhibiting endothelial cell and fibrinogen mediated inflammation within a patient by administering a homolog of this invention are also contemplated.
Type:
Grant
Filed:
April 25, 1994
Date of Patent:
February 4, 1997
Assignee:
The Scripps Research Institute
Inventors:
Dario C. Altieri, Lucia R. Languino, George B. Thornton
Abstract: Diagnostic systems, methods, polypeptides and antibodies for detecting the presence of the cytoplasmic domain of the integrin .alpha..sub.6B or .alpha..sub.3B subunit in a body sample are disclosed.